Ledger Run
Ledger Run is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
C4931004 - A Phase 3, Randomized Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Catch-Up Vaccination Regimen of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Children and Adolescents
Sponsor Pfizer Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants with Refractory Chronic Cough
Sponsor Trevi Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
An Open Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB 11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer
Sponsor Jazz Pharmaceuticals Ireland Limited
- Start (EU)
- Latest update
- Estimated end
APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Sponsor Disc Medicine Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
Sponsor Generate Biomedicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
Sponsor Generate Biomedicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer’s Disease
Sponsor Acumen Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ledger Run?
The 2026-10-09 snapshot links Ledger Run to 14 distinct CTIS trials. Recorded services include Payment services, Administrative, Contract negotiation, Clinical Trial Contracting, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ledger Run?
The most frequently recorded therapeutic areas are Haematological Malignancies, Respiratory, Solid Tumor Oncology, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ledger Run conducted?
The linked trials record locations in 23 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where Ledger Run delivered services.
What can this page tell me about Ledger Run's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Ledger Run. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ledger Run
- Ledger Run Inc.